34233-69-7
中文名称
氯氮平-N-氧化物
英文名称
CLOZAPINE N-OXIDE
CAS
34233-69-7
分子式
C18H19ClN4O
分子量
342.82
MOL 文件
34233-69-7.mol
更新日期
2025/05/14 11:25:41
34233-69-7 结构式
基本信息
中文别名
氯氮平氮氧化合物氯氮平 N-氧化物
MAJORMETABOLITEOFCLOZAPINE.POSSESSESLITTLEORNOACTIVITYAT5-HTRECEPTORS
英文别名
CLOZAPINE N-OXIDEClozapine N-oxide solution
Clozapine N-oxide Methanol Adduct
e)(1,4)diazepine,8-chloro-11-(4-methyl-1-piperazinyl)-5h-dibenzo(n-oxide
8-CHLORO-11-[4-METHYL-1-PIPERAZINYL]-5H-DIBENZO[B,E][1,4]DIAZEPINE N-OXIDE
所属类别
生物化工：激动剂抑制剂物理化学性质
熔点190-248°C
闪点9℃
储存条件-20°C Freezer, Under Inert Atmosphere
溶解度溶于二甲基亚砜。
酸度系数(pKa)6.86±0.20(Predicted)
形态粉末
颜色黄色
生物来源synthetic
稳定性Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
InChIKeyOGUCZBIQSYYWEF-UHFFFAOYSA-N
安全数据
警示词危险
危险性描述H301-H336
防范说明P301+P310+P330
危险品标志Xn,T,F
危险品运输编号UN 2811 6.1/PG 3
危险品运输编号UN 2811 6.1/PG 3
WGK Germany3
WGK Germany3
RTECS号HP1760000
危险等级6.1(b)
包装类别III
海关编码29335990
氯氮平-N-氧化物价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-17366 | 氯氮平-N-氧化物 Clozapine N-oxide | 34233-69-7 | 5mg | 750元 |
| 2025/02/08 | HY-17366 | 氯氮平-N-氧化物 Clozapine N-oxide | 34233-69-7 | 10mM * 1mLin DMSO | 825元 |
| 2025/02/08 | HY-17366 | 氯氮平-N-氧化物 Clozapine N-oxide | 34233-69-7 | 10mg | 1100元 |
常见问题列表
生物活性
Clozapine N-oxide (CNO) 是一种 Clozapine (GLXC-06516) 的代谢产物，是 human muscarinic designer receptors (Designer Receptors Exclusively Activated by Designer Drugs, DREADDs) 的激动剂。Clozapine 是一种有效的 dopamine (DA) 拮抗剂和选择性的 muscarinic M4 receptor 的激动剂。靶点
| Target | Value |
|
DREADD
() | |
|
Dopamine receptor
() | |
|
muscarinic M4 receptor
() |
体外研究
Clozapine N-oxide (CNO) can bind to non-DREADD receptors at concentrations required for DREADD activation, and undergoes reverse-metabolism to its parent compound clozapine, an atypical antipsychotic that acts at a variety of pharmacological targets and produces numerous physiological and behavioral effects.
体内研究
After a single intraperitoneal (i.p.) injection of Clozapine N-oxide (1 mg/kg) into mice, Clozapine N-oxide (CNO) plasma levels peak at 15 min and are very low after 2 h. Despite the short plasma half-life of CNO in mice, the biological effects that have been described after acute treatment of DREADD-expressing experimental animals are usually much longer (6-10 h).